cas 1446507-39-6|| where to buy 2,4-Dichloro-6-(6-chloro-2-pyridyl)-1,3,5-triazine

Product Name:2,4-Dichloro-6-(6-chloro-2-pyridyl)-1,3,5-triazine

IUPAC Name:2,4-dichloro-6-(6-chloropyridin-2-yl)-1,3,5-triazine

Packing Unit	Available Stock	Price($)
CM386040-100mg	in stock	șƻǕ
CM386040-250mg	in stock	ƻȋň
CM386040-1g	in stock	ňǕƏƅ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:1446507-39-6; Molecular Formula:C8H3Cl3N4; Melting Point:-; Smiles Code:ClC1=CC=CC(=N1)C1=NC(Cl)=NC(Cl)=N1; Density:

: Catalog Number:CM386040; Molecular Weight:261.49; Boiling Point:; MDL No:; Storage:

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Vorasidenib; Servier presented the latest clinical data on the IDH1/2 inhibitor vorasidenib (AG-881) in the treatment of IDH-mutated diffuse glioma at the 28th Annual Meeting of the Society of Neuro-Oncology (SNO). Blinded independent radiology committee evaluation showed that vorasidenib significantly reduced tumor growth and not only preserved the patient's quality of life, but also stabilized neurocognitive function and controlled epilepsy. Based on these results, the company plans to submit a new drug application for vorasidenib to the U.S. FDA by the end of 2023 for the treatment of IDH-mutated diffuse glioma. Vorasidenib is an oral, brain-penetrating and selective dual inhibitor under development that can inhibit mutated IDH1/2 proteins and is a potential "first-in-class" drug. It has received breakthrough therapy designation from the FDA.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.